Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX), Bausch + Lomb Corporation (BLCO) and UnitedHealth (UNH).
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurocrine (NBIX)
Truist Financial analyst Danielle Brill maintained a Buy rating on Neurocrine today. The company’s shares closed last Monday at $132.48.
According to TipRanks.com, Brill is a 5-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $183.33, representing a 40.0% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $185.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Bausch + Lomb Corporation (BLCO)
In a report released today, Thomas Stephan from Stifel Nicolaus maintained a Hold rating on Bausch + Lomb Corporation, with a price target of $16.34. The company’s shares closed last Monday at $16.34.
According to TipRanks.com, Stephan is a 2-star analyst with an average return of
Currently, the analyst consensus on Bausch + Lomb Corporation is a Hold with an average price target of $18.76, which is a 13.4% upside from current levels. In a report issued on March 23, Goldman Sachs also maintained a Hold rating on the stock with a $19.00 price target.
UnitedHealth (UNH)
Bernstein analyst Lance Wilkes assigned a Buy rating to UnitedHealth yesterday and set a price target of $405.00. The company’s shares closed last Monday at $281.36.
According to TipRanks.com, Wilkes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $369.25 average price target, a 32.9% upside from current levels. In a report issued on April 1, Raymond James also upgraded the stock to Buy with a $330.00 price target.
Read More on NBIX:
Disclaimer & DisclosureReport an Issue
- Neurocrine price target raised to $199 from $190 at BofA
- Balanced Risk-Reward After Soleno Acquisition Supports Neutral Stance on Neurocrine
- Neurocrine price target raised to $215 from $192 at H.C. Wainwright
- Neurocrine price target raised to $166 from $151 at Baird
- Neurocrine price target raised to $242 from $204 at Citi
